CTLA4 and neoplasm: First, a small trial showed that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generated clinically meaningful antitumor immunity in a majority of metastatic melanoma patients (61).